Skip to main content

Advertisement

SpringerLink
Log in

Assessing Topical Bioavailability and Bioequivalence: A Comparison of the In vitro Permeation Test and the Vasoconstrictor Assay

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose

To compare the sensitivity of a pharmacokinetic assay, the in vitro permeation test (IVPT), with that of a pharmacodynamic assay, the human skin blanching or vasoconstrictor (VC) assay, in assessing the relative bioavailability of topical clobetasol propionate products.

Methods

The percutaneous absorption of clobetasol propionate from five commercial products was measured in vitro using cryopreserved human skin. The pharmacodynamic potency of the same five products was also assessed in vivo using the VC assay, the surrogate method by which regulatory authorities in the United States establish the bioequivalence of generic topical glucocorticoid products.

Results

IVPT found total clobetasol absorption varying ten-fold from highest to lowest product, whereas the VC assay found this same difference was less than two-fold. The coefficient of variation ranged from 78 to 126% in the VC assay, but only 30–43% for IVPT. Statistically, IVPT could separate the 5 products into three groups: 1) ointment, 2) cream and gel, 3) emollient cream and solution). Due to its greater variability as well as saturation of the pharmacodynamic response at higher flux levels, the VC assay found all products except the solution to be equipotent.

Conclusions

IVPT was found to be substantially more sensitive and less variable than the VC assay for assessing clobetasol bioavailability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Franz TJ, Lehman PA, Raney SG. The cadaver skin absorption model and the drug development process. Pharmacopeial Forum. 2008;34(5):1349–56.

    Google Scholar 

  2. Skelly JP, Shah VP, Maibach HI, Guy RH, Wester RC, Flynn G, et al. FDA and AAPS report of the workshop on principles and practices of in vitro percutaneous penetration studies: relevance to bioavailability and bioequivalence. Pharm Res. 1987;4(3):265–7.

    Article  Google Scholar 

  3. Lehman PA, Raney SG, Franz TJ. Percutaneous absorption in man: in vitro-in vivo correlation. Skin Pharmacol Physiol. 2011;24(4):224–30.

    Article  CAS  PubMed  Google Scholar 

  4. Franz TJ, Lehman PA, Raney SG. Use of excised human skin to assess the bioequivalence of topical products. Skin Pharmacol Physiol. 2009;22(5):276–86.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38(8):628–32.

    Article  CAS  PubMed  Google Scholar 

  6. McKenzie AW, Stoughton RB. Methods for comparing percutaneous absorption of steroids. Arch Dermatol. 1962;86:608–10.

    Article  Google Scholar 

  7. US FDA. Guidance for Industry, Topical Dermatologic Corticosteroids: In Vivo Bioequivalence. VC Guidance. Center for Drug Evaluation and Research, Rockville, MD1995.

  8. Games PA, Howell JF. Pairwise multiple comparison procedures with unequal n’s and/or variances: a Monte Carlo study. J Educ Stat. 1976;1:113–25.

    Article  Google Scholar 

  9. US FDA. Approval Package, ANDA 75–430, Clobetasol Propionate Emollient Cream 0.05%. Bioequivalence Review. Center for Drug Evaluation and Research, Rockville, MD http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/75-430_clobetasol.cfm

  10. US FDA. Approval Package, ANDA 75–279, Clobetasol Propionate Gel 0.05%. Bioequivalence Review. Center for Drug Evaluation and Research, Rockville, MD http://www.accessdata.fda.gov/drugsatfda_docs/anda/99/075279_clobetasol_toc.cfm

  11. US FDA. Approval Package, ANDA 75–633, Clobetasol Propionate Emollient Cream 0.05%. Bioequivalence Review. Center for Drug Evaluation and Research, Rockville, MD http://www.accessdata.fda.gov/drugsatfda_docs/anda/2001/075733_clobetasol_propionate_toc.cfm

  12. US FDA. Approval Package, ANDA 75–733, Clobetasol Propionate Emollient Cream 0.05%. Bioequivalence Review. Center for Drug Evaluation and Research, Rockville, MD http://www.accessdata.fda.gov/drugsatfda_docs/anda/2001/075733_clobetasol_propionate_toc.cfm.

  13. US FDA. Approval Package, ANDA 78–223, Clobetasol Propionate Lotion 0.05%. Bioequivalence Review. Center for Drug Evaluation and Research, Rockville, MD http://www.accessdata.fda.gov/drugsatfda_docs/anda/2008/078223Orig1s000.pdf

  14. Stoughton RB, Wullich K. Relation of application time to bioactivity of a potent topical glucocorticoid formulation. J Am Acad Dermatol. 1990;22(6 Pt 1):1038–41.

    Article  CAS  PubMed  Google Scholar 

  15. Fang JY, Shen KL, Huang YB, Wu PC, Tsai YH. Evaluation of topical application of clobetasol 17-propionate from various cream bases. Drug Dev Ind Pharm. 1999;25(1):7–14.

    Article  CAS  PubMed  Google Scholar 

  16. McKenzie AW. Percutaneous absorption of steroids. Arch Dermatol. 1962;86:611–4.

    Article  Google Scholar 

  17. Scheuplein RJ, Ross LW. Mechanism of percutaneous absorption. V. Percutaneous absorption of solvent deposited solids. J Invest Dermatol. 1974;62(4):353–60.

    Article  CAS  PubMed  Google Scholar 

  18. Franz TJ, Lehman PA. Percutaneous absorption. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker; 1995. p. 413–47.

    Google Scholar 

  19. Anissimov YG, Roberts MS. Diffusion modeling of percutaneous absorption kinetics: 2. Finite vehicle volume and solvent deposited solids. J Pharm Sci. 2001;90(4):504–20.

    Article  CAS  PubMed  Google Scholar 

  20. Harding SM, Sohail S, Busse MJ. Percutaneous absorption of clobetasol propionate from novel ointment and cream formulations. Clin Exp Dermatol. 1985;10(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  21. US FDA. Medical Officer’s Review of NDA19-966, Temovate (clobetasol propionate) Scalp Application 0.05%. Center for Drug Evaluation and Research, Rockville, MD http://www.fda.gov/RegulatoryInformation/FOI/HowtoMakeaFOIARequest/default.htm

  22. US FDA. Medical Officer’s Review of NDA19-968, Ultravate (halobetasol propionate) Ointment 0.05%. Center for Drug Evaluation and Research, Rockville, MD, http://www.fda.gov/RegulatoryInformation/FOI/HowtoMakeaFOIARequest/default.htm

  23. US FDA. Clinical Review of NDA 20–337, Temovate (clobetasol propionate) Gel 0.05%. Center for Drug Evaluation and Research, Rockville, MD. http://www.fda.gov/RegulatoryInformation/FOI/HowtoMakeaFOIARequest/default.htm

  24. US FDA. Clinical Review of NDA 20–340, Temovate (clobetasol propionate) Emollient Cream 0.05%. Center for Drug Evalustion and Research, Rockville, MD. http://www.fda.gov/RegulatoryInformation/FOI/HowtoMakeaFOIARequest/default.htm

  25. Physicians Desk Reference. 58 ed. Montvale, NJ: Thomson PDR; 2004.

  26. Wiedersberg S, Naik A, Leopold CS, Guy RH. Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability. Br J Dermatol. 2009;160(3):676–86.

    Article  CAS  PubMed  Google Scholar 

  27. Stoughton RB. Vasoconstricto Assay - Specific Applications. In: Maibach HI, Surber C, editors. Topical Corticosteroids. Basel: S. Karger; 1992. p. 42–53.

  28. US FDA. Summary basis of approval, NDA 20–934, Luxiq (Betamethasone Valerate) foam, clinical pharmacology and biopharmaceutics review. Rockville: Center for Drug Evaluation and Research; 1999.

    Google Scholar 

  29. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol. 1985;121(1):63–7.

    Article  CAS  PubMed  Google Scholar 

  30. US FDA. Summary Basis of Approval, NDA 21–535, Clobex (Clobetasol Propionate) Lotion 0.05%, Clinical Pharmacology and Biopharmaceutics Review. Center for Drug Evaluation and Research, Rockville, MD http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-535_Clobex_BioPharmr.pdf.

Download references

Acknowledgments and Disclosures

We would like to express our appreciation to Dr. Adrian Davis for his insight and helpful comments regarding the results of this study.

Author information

Authors and Affiliations

  1. QPS Holdings, LLC, 3 Innovation Way, Suite 240, Newark, Delaware, 19711, USA

    Paul A. Lehman

  2. 10716 SE Forest View Lane, Happy Valley, Oregon, 97086, USA

    Thomas J. Franz

Authors
  1. Paul A. Lehman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas J. Franz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas J. Franz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lehman, P.A., Franz, T.J. Assessing Topical Bioavailability and Bioequivalence: A Comparison of the In vitro Permeation Test and the Vasoconstrictor Assay. Pharm Res 31, 3529–3537 (2014). https://doi.org/10.1007/s11095-014-1439-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-014-1439-7

Key Words

Search

Navigation